Dry age-related macular degeneration (AMD) is a retinal disease affecting millions of people worldwide and can lead to progressive and irreversible vision loss. Currently, no curative treatment is available for this form of AMD.
In response to this major unmet medical need, a team from the Department of Ophthalmology at Geneva University Hospitals (HUG) and the Faculty of Medicine at the University of Geneva, in collaboration with the Experimental Ophthalmology Lab, is conducting an innovative clinical study focused on stem cell–based therapies.
The study explores the development of therapeutic cells derived from urine samples, a non-invasive and promising method. The aim is to better understand how these cells could be used to treat dry AMD and, in the long term, pave the way for new therapeutic options for patients.
The study is open to:
Every participant plays a key role in advancing research for a disease where therapeutic options are still limited.
By supporting and sharing this initiative, the Fondation pour Recherches Médicales reinforces its commitment to translational research and innovation in visual health.
👉 Learn more and participate:
https://recherche.hug.ch/etudes/etude-sur-les-cellules-souches-pour-traiter-une-maladie-de-la-retine
